Be the first to review this item
Katadolon (Flupirtinum, Flupirtine) - non-narcotic analgesic agent. Flupirtine (Flupirtinum) is the prototype of a new class of substances SNEPCO ( «Selective Neuronal Potassium Channel Opener» - «selective neuronal potassium channel activators").
It refers to non-opioid analgesics central action without causing dependence and addiction.
Flupirtine has analgesic, muscle relaxant and neuroprotective effect based on indirect antagonism against NMDA (N-methyl-D-aspartate) - receptor to activate downstream mechanisms in pain modulation and GABAergic processes.
At therapeutic concentrations, flupirtine does not bind to alpha 1 -, alfa2-, 5NT1, 5NT2-, dopamine, benzodiazepine, opiate, central muskarinergicheskimi or nikotinergicheskimi receptors.
Antispasmodic effect on the muscle to block the transfer of excitation in the motor neurons of the intermediate neurons, leading to the removal of muscle tension. This action of flupirtine is manifested in many chronic diseases accompanied by painful muscle spasms (musculoskeletal pain in the neck and back pain, arthropathy, tenzionnye headaches, fibromyalgia).
Neuroprotective properties of the drug are responsible for the protection of the nervous structures of the toxic effect of high concentrations of intracellular calcium ions, which is due to its ability to cause a blockade of neuronal ionic calcium channels and lower intracellular calcium ion current.
For the treatment of acute and chronic pain caused by:
With care prescribe a drug to patients with impaired liver and / or kidney disease, patients older than 65 years.
In patients with reduced kidney function or liver should monitor the activity of liver enzymes and creatinine in the urine.
In patients older than 65 years or with pronounced signs of renal and / or hepatic impairment or hypoalbuminemia necessary to carry out the dose adjustment.
In the treatment of flupirtine possible false positive reactions with diagnostic test strips for bilirubin, urobilinogen and protein in urine. A similar reaction is possible in the quantitative determination of bilirubin in the blood plasma.
In applying the drug in high doses, in some cases there may be a urine stain in the color green, which is not a clinical sign of any disease.
Given that flupirtine can attenuate attention and slow responses of the body, it is recommended during treatment with refrain from driving and transport activities potentially hazardous activities that require high concentration and psychomotor speed reactions.
Symptoms: nausea, tachycardia, a state of prostration, crying, confusion, dry mouth.
Treatment: gastric lavage, forced diuresis, administration of activated carbon and electrolyte. Symptomatic treatment. No specific antidote.
Katadolon Inside, with liquid squeezed small amount of liquid (100 ml).
Adults: 1 capsule 3-4 times a day at regular intervals between doses.
When expressed pain - 2 capsules 3 times a day.
The maximum daily dose should not exceed 600 mg (corresponding to 6 capsules).
Doses are selected depending on the intensity of pain and the patient's individual susceptibility to the drug.
Patients older than 65 years: in the beginning of treatment, 1 capsule in the morning and evening. The dose may be increased to 300 mg depending on the intensity of pain and tolerability.
In patients with severe renal insufficiency or hypoalbuminemia daily dose should not exceed 300 mg (3 capsules).
In patients with impaired liver function the daily dose should not exceed 200 mg (2 capsules). The appointment of higher doses of the drug for patients establish close observation.
The duration of therapy is determined by the attending physician and depends on the dynamics of pain and tolerance.
It enhances the effect of alcohol, sedatives and muscle relaxants.
Due to the fact that flupirtine protein bound, one should consider the possibility of its replacement by other medications taken concurrently.
Thus, it is shown that warfarin and diazepam flupirtine are displaced from the protein binding that while their reception can lead to an enhancement of their activity.
When concomitant administration of flupirtine and coumarin derivatives should regularly monitor the performance of Quick (prothrombin index) in order to avoid possible action or to reduce the dose of coumarin.
Data on the interaction with other anticoagulant and antiplatelet agents is not (acetylsalicylic acid, etc..).
With simultaneous use of flupirtine with drugs that are also metabolized by the liver, it requires regular monitoring of the level of "liver" enzymes.
Avoid combined use of flupirtine and medicines containing paracetamol and carbamazepine.
The most common (> 10% of cases), weakness (15% of patients), which is found at the beginning of treatment.
Often (from 1% to 10%): dizziness, heartburn, nausea, vomiting, constipation / or diarrhea, flatulence, abdominal pain, dry mouth, loss of appetite, depression, sleep disturbances, sweating, restlessness, nervousness, tremors, headache, pain.
Rarely (from 0.1% to 1%): confusion, visual disturbances, and allergic reactions (fever, hives and itching).
Very rarely (less than 0.01%): increased activity of "liver" transaminases (after discontinuation return to normal), hepatitis (acute or chronic, flowing with jaundice or without jaundice, with or without elements of cholestasis).
Side effects depend mainly on the dose. In many cases they disappear on their own as of or after the end of treatment.
Important notice- the outer box design may vary before prior notice!
Someone from the Qatar - just purchased the goods:
Sofradex eye drops 5ml